Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Autor: Weller, M, Butowski, N, Tran, DD, Recht, LD, Lim, M, Hirte, H, Ashby, L, Mechtler, L, Goldlust, SA, Iwamoto, F, Drappatz, J, O'Rourke, DM, Wong, M, Hamilton, MG, Finocchiaro, G, Perry, J, Wick, W, Green, J, He, Y, Turner, CD, Yellin, MJ, Keler, T, Davis, TA, Stupp, R, Sampson, JH, Campian, J, Recht, L, Goldlust, S, Becker, K, Barnett, G, Nicholas, G, Desjardins, A, Benkers, T, Wagle, N, Groves, M, Kesari, S, Horvath, Z, Merrell, R, Curry, R, O'Rourke, J, Schuster, D, Mrugala, M, Jensen, R, Trusheim, J, Lesser, G, Belanger, K, Sloan, A, Purow, B, Fink, K, Raizer, J, Schulder, M, Nair, S, Peak, S, Brandes, A, Mohile, N, Landolfi, J, Olson, J, Jennens, R, DeSouza, P, Robinson, B, Crittenden, M, Shih, K, Flowers, A, Ong, S, Connelly, J, Hadjipanayis, C, Giglio, P, Mott, F, Mathieu, D, Lessard, N, Sepulveda, SJ, Lövey, J, Wheeler, H, Inglis, PL, Hardie, C, Bota, D, Lesniak, M, Portnow, J, Frankel, B, Junck, L, Thompson, R, Berk, L, McGhie, J, Macdonald, D, Saran, F, Soffietti, R, Blumenthal, D, André de, SBCM, Nowak, A

Publikováno v: Weller, M; Butowski, N; Tran, DD; Recht, LD; Lim, M; Hirte, H; et al.(2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet Oncology, 18(10), 1373-1385. doi: 10.1016/S1470-2045(17)30517-X. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/2sg9m5wp

© 2017 Elsevier Ltd Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6bdef254233643727bdc6e1e7e8761af
http://www.escholarship.org/uc/item/2sg9m5wp

Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation.

Autor: Kramer, J H, Crittenden, M R, DeSantes, K, Cowan, M J

Publikováno v: Bone Marrow Transplantation. 3/15/97, Vol. 19 Issue 6, p607. 7p.

72P - Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Autor: Moreno, V., Gil-Martin, M., Johnson, M.L., Aljumaily, R., Lopez Criado, P., Northfelt, D.W., Crittenden, M., Jabbour, S., Rosen, L., Garrido, P., Hervás Morón, A., Rietschel, P., Mohan, K.K., Li, J., Stankevich, E., Feng, M., Lowy, I., Fury, M.G.

Publikováno v: In Annals of Oncology December 2018 29 Supplement 10:x26-x26

73P - Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study

Autor: He, A.R., Weiss, G.J., Falchook, G., Yee, N.S., Gil-Martin, M., Shahda, S., Moreno, V., Brana, I., Crittenden, M., Formenti, S., Al-Rajabi, R., Papadopoulos, K.P., Pishvaian, M.J., Stankevich, E., Feng, M., Li, J., Mathias, M., Kroog, G., Lowy, I., Fury, M.G.

Publikováno v: In Annals of Oncology December 2018 29 Supplement 10:x26-x26